Bayer(US:BAYRY) Xin Lang Cai Jing·2025-12-20 15:38Core Insights - Bayer's stock has rebounded significantly from its low in April 2023, currently trading around €35.50, despite previous pressures from lawsuits related to glyphosate since the acquisition of Monsanto in 2017 [3] - Analysts have reaffirmed "buy" or "hold" ratings for Bayer, with some, like JPMorgan, setting a target price as high as €50 [3] Investment Strategy - Investors who believe Bayer's stock is "slightly overvalued" but still want to participate in potential upside while reducing direct stock holding risks may consider investing in capped bonus certificates [4] - These products offer potential returns during stock price increases and can still yield high returns even if the stock price remains flat or declines [4] Mechanism of the Investment Product - The bonus certificate will pay out €40 if Bayer's stock does not touch or fall below the barrier price of €24 during the observation period, which ends on March 25, 2027 [5] - The certificate, issued by BNP Paribas, has a market price of approximately €32.67 when Bayer's stock is at €35.50, requiring less capital than direct stock purchase [6] Return Potential - If an investor buys the certificate at €32.67 and Bayer's stock does not drop to €24 or lower, a gross return of 22.44% can be achieved by March 2027, equating to an annualized return of about 18% [7]